Phylicia Aaron
Impact in
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment
-
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- CAR-T cell therapy research
Papers in
- Oncology 11
- PARP inhibition in cancer therapy 7
- Cancer Immunotherapy and Biomarkers 4
-
- Immunotherapy and Immune Responses 3
- Co-authors
- Angie Gelli (4 shared papers)John Nemunaitis (15 shared papers)Laura Stanbery (11 shared papers)Luisa Manning (13 shared papers)Mantana Jamklang (1 shared paper)Ernest Bognar (13 shared papers)Staci Horvath (7 shared papers)Gladice Wallraven (6 shared papers)
- Journals
- Journal of Clinical Oncology (3 papers)Gynecologic Oncology (3 papers)Cancer Gene Therapy (2 papers)ACS Infectious Diseases (1 paper)Antimicrobial Agents and Chemotherapy (1 paper)
- Partner nations
- United StatesQatar
In The Last Decade
Phylicia Aaron
20 papers receiving 293 citations
Peers
Comparison fields: 5 of 58
- Reproductive Medicine 47
- Oncology 138
- Immunology 94
- Microbiology 2
- Infectious Diseases 46
Countries citing papers authored by Phylicia Aaron
This map shows the geographic impact of Phylicia Aaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phylicia Aaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phylicia Aaron more than expected).
Fields of papers citing papers by Phylicia Aaron
This network shows the impact of papers produced by Phylicia Aaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phylicia Aaron. The network helps show where Phylicia Aaron may publish in the future.
Co-authors
The 25 scholars most cited alongside Phylicia Aaron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 55 | |
| 2 | 2020 | 49 | |
| 3 | 2021 | 26 | |
| 4 | 2021 | 21 | |
| 5 | 2020 | 20 | |
| 6 | 2020 | 19 | |
| 7 | 2022 | 17 | |
| 8 | 2021 | 15 | |
| 9 | 2020 | 14 | |
| 10 | 2021 | 13 | |
| 11 | 2019 | 12 | |
| 12 | 2020 | 10 | |
| 13 | 2018 | 9 | |
| 14 | 2021 | 5 | |
| 15 | 2021 | 4 | |
| 16 | 2020 | 3 | |
| 17 | 2020 | 3 | |
| 18 | 2020 | 3 | |
| 19 | 2020 | 1 | |
| 20 | A case of Fabry disease (alpha-galactosidase A deficiency). | 1994 | 1 |
About Phylicia Aaron
Phylicia Aaron is a scholar working on Oncology, Immunology, Molecular Biology, Genetics and Biotechnology, having authored 20 papers that have together received 300 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (7 papers), Ovarian cancer diagnosis and treatment (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Cancer Research and Treatments (4 papers), Immunotherapy and Immune Responses (3 papers), Virus-based gene therapy research (3 papers), Cancer Genomics and Diagnostics (2 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Reproductive Medicine (47 citations), Oncology (138 citations), Immunology (94 citations), Microbiology (2 citations) and Infectious Diseases (46 citations). Phylicia Aaron has collaborated with scholars based in United States and Qatar. Frequent co-authors include Angie Gelli, John Nemunaitis, Laura Stanbery, Luisa Manning, Mantana Jamklang, Ernest Bognar, Staci Horvath, Gladice Wallraven, Rodney P. Rocconi and Kiem Vu. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Cancer Gene Therapy, ACS Infectious Diseases and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.